Skip to content

Ezio Bettini

2 papers in the library · publishing 2021-2022

Papers

Sort Most recent Most cited

Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling.

International Journal of Molecular Sciences October 13, 2022 Stephen M Stahl, Sara de Martin, Andrea Mattarei et al.

This article presents a mechanism of action hypothesis to explain the rapid antidepressant effects of esmethadone (REL-1017) and other uncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonists and presents a corresponding mechanism of disease hypothesis for major depressive disorder (MDD). Esmethadone and other uncompetitive NMDAR antagonists may restore physiological neural plasticity in...

REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial.

American Journal of Psychiatry December 22, 2021 Maurizio Fava, S. Stahl, Luca Pani et al.

OBJECTIVE The purpose of this study was to examine the effects of REL-1017 (esmethadone), a novel N-methyl-d-aspartate receptor (NMDAR) channel blocker, in patients with major depressive disorder who failed to benefit from one to three standard antidepressant treatments in their current major depressive episode. METHODS A 7-day phase 2 multicenter randomized double-blind placebo-controlled...